227023-76-9

Upstream product

• 227023-75-8 (S)-[2-(4-Benzyloxy-5-methoxy-2-phenylacetylamino-phenyl)-2-(4-cyano-phenylamino)-acetylamino]-phenyl-acetic acid 
• 2426-84-8 4-(benzyloxy)-5-methoxy-2-nitrobenzaldehyde 
• 15028-39-4 L-2-phenylglycine methyl ester hydrochloride 
• 103-80-0 phenylacetyl chloride 
• 873-74-5 4-Aminobenzonitrile 
• 227023-67-8 methyl (RS)-(2-amino-4-benzyloxy-5-methoxy-phenyl)-(4-cyano-phenylamino)-acetate 
• 227023-66-7 (4-Benzyloxy-5-methoxy-2-nitro-phenyl)-(4-cyano-phenylamino)-acetic acid methyl ester 
• 277325-19-6 methyl (RS)-(4-benzyloxy-5-methoxy-2-phenylacetylamino-phenyl)-(4-cyano-phenylamino)-acetate 
• 227023-74-7 (S)-[2-(4-Benzyloxy-5-methoxy-2-phenylacetylamino-phenyl)-2-(4-cyano-phenylamino)-acetylamino]-phenyl-acetic acid methyl ester 

Relevant academic research and scientific papers

Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors

Proof of concept experiments have shown that tissue factor/factor VIIa inhibitors have antithrombotic activity without enhancing bleeding propensity. Starting from lead compounds generated by a biased combinatorial approach, phenylglycine amide tissue fac